A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells

Cancer Medicine, EarlyView.


from Cancer via ola Kala on Inoreader https://ift.tt/2Iofnxr
via IFTTT